Back to Agenda
Session 2 (Continued) - Diabetic Drug Development and CV Safety
Speaker(s)
HOW NEW REGULATIONS WILL IMPACT THE CLINICAL DEVELOPMENT OF NEW TYPE 2 DM MEDICATIONS
Shamik Parikh, MD
AstraZeneca, United States
Executive Director, Clinical Development, CV/GI
PANEL DISCUSSION: T2DM DRUG DEVELOPMENT: HOW LARGE IS THE SAFETY ISSUE AND ASSESSMENT CONSIDERATIONS?
Mary Parks, MD
FDA, United States
Director, Div. of Endocrinology and Metabolism Prod., ODE II, CDER
Have an account?